MXPA06012500A - Compuestos para el tratamiento de la enfermedad de alzheimer y para la inhibicion de la produccion del peptido beta-amiloideo. - Google Patents

Compuestos para el tratamiento de la enfermedad de alzheimer y para la inhibicion de la produccion del peptido beta-amiloideo.

Info

Publication number
MXPA06012500A
MXPA06012500A MXPA06012500A MXPA06012500A MXPA06012500A MX PA06012500 A MXPA06012500 A MX PA06012500A MX PA06012500 A MXPA06012500 A MX PA06012500A MX PA06012500 A MXPA06012500 A MX PA06012500A MX PA06012500 A MXPA06012500 A MX PA06012500A
Authority
MX
Mexico
Prior art keywords
disease
compounds
amyloid peptide
treating alzheimer
treating
Prior art date
Application number
MXPA06012500A
Other languages
English (en)
Inventor
Kim Tae-Wan
Chung Sungkwon
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of MXPA06012500A publication Critical patent/MXPA06012500A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invencion proporciona composiciones y metodos para el tratamiento y prevencion de la enfermedad de Alzheimer mediante la administracion a un sujeto de una cantidad efectiva de un compuesto de dammarane o ginsenoside. La invencion tambien proporciona las composiciones y los metodos para modular la produccion de proteinas b-amiloideas, entre las que se incluyen A??42 en una celula. La invencion demas proporciona las composiciones y los metodos para el tratamiento y prevencion de la neurodegeneracion mediante la administracion a un sujeto de una cantidad efectiva de un compuesto de dammarane o ginsenoside. Adicionalmente la invencion proporciona los equipos para utilizarse en el tratamiento y/o prevencion de la enfermedad de Alzheimer y la neurodegeneracion, asi como tambien para reducir la produccion de la proteina b-amiloidea.
MXPA06012500A 2004-04-28 2005-04-28 Compuestos para el tratamiento de la enfermedad de alzheimer y para la inhibicion de la produccion del peptido beta-amiloideo. MXPA06012500A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/834,773 US20050245465A1 (en) 2004-04-28 2004-04-28 Compounds for treating Alzheimer's disease and for inhibiting beta-amyloid peptitde production
PCT/US2005/014659 WO2006124012A2 (en) 2004-04-28 2005-04-28 Compounds for treating alzheimer's disease and for inhibiting beta-amyloid peptide production

Publications (1)

Publication Number Publication Date
MXPA06012500A true MXPA06012500A (es) 2007-07-11

Family

ID=35187878

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06012500A MXPA06012500A (es) 2004-04-28 2005-04-28 Compuestos para el tratamiento de la enfermedad de alzheimer y para la inhibicion de la produccion del peptido beta-amiloideo.

Country Status (8)

Country Link
US (1) US20050245465A1 (es)
EP (1) EP1745060A4 (es)
JP (1) JP2007535578A (es)
KR (1) KR20070033977A (es)
CN (1) CN101133075A (es)
CA (1) CA2565002A1 (es)
MX (1) MXPA06012500A (es)
WO (1) WO2006124012A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006118630A2 (en) * 2005-05-02 2006-11-09 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of alzheimer's disease
EP2083621A4 (en) * 2006-11-20 2010-03-24 Satori Pharmaceuticals Inc MODULATORS OF AMYLOID BETA PRODUCTION
CN102552298A (zh) * 2008-03-31 2012-07-11 中国医学科学院药物研究所 Rh1抗认知、学习记忆功能障碍的用途
CN102796159B (zh) * 2011-05-24 2014-12-03 复旦大学 一类达玛烷糖苷及其制备方法与应用
CN102229651A (zh) * 2011-06-08 2011-11-02 中南大学 一种治疗阿尔茨海默病的淀粉样蛋白膜内片段及其应用
WO2014132430A1 (ja) * 2013-03-01 2014-09-04 金氏高麗人参株式会社 ジンセノサイド組成物
KR101548605B1 (ko) * 2013-11-11 2015-09-01 서울대학교산학협력단 인삼 분획물 또는 이로부터 분리된 진세노사이드를 함유하는 시르투인 활성화로 치료되는 질환의 예방 또는 치료용 조성물
CN104644658A (zh) * 2013-11-22 2015-05-27 富力 人参皂苷Rg3在制备用于预防或/和治疗痴呆病症药物中的应用及药物
US20160022751A1 (en) * 2014-07-23 2016-01-28 Gangneung-Wonju National University Industry Academy Cooperation Group Novel composition for treating alzheimer's disease and improving cognitive function of alzheimer's patients
KR101751392B1 (ko) * 2015-05-22 2017-06-29 한국과학기술원 미토콘드리아 분열 조절제의 스크리닝 방법
KR101777920B1 (ko) * 2015-07-27 2017-09-14 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 진세노사이드 f1을 포함하는 아밀로이드 플라크 제거용 조성물
CN106109483B (zh) * 2016-07-29 2020-02-07 陕西巨子生物技术有限公司 具有抗肿瘤活性的二醇组/三醇组稀有人参皂苷组合物
CN106538563B (zh) * 2016-10-26 2019-01-22 中国中医科学院中药研究所 人参皂苷混合物及其在作为植物生长调节剂中的应用
CN107441104B (zh) * 2017-08-24 2023-07-21 浙江大学 人参二醇皂苷Rb组分防治糖尿病并发症及代谢紊乱相关疾病的医药用途
CN107556362B (zh) * 2017-09-15 2020-05-22 浙江大学 葫芦烷型三萜化合物的提取方法及抗阿尔兹海默症医药用途
CN111265536B (zh) * 2020-03-31 2021-04-13 陕西巨子生物技术有限公司 包含稀有人参皂苷Rk2、CK和PPT的抗肿瘤组合物
KR102534935B1 (ko) * 2020-12-02 2023-05-22 한양대학교 에리카산학협력단 진세노사이드를 유효성분으로 포함하는 알츠하이머 예방 또는 치료용 약학적 조성물
CN115429824B (zh) * 2021-06-05 2023-10-24 北京中医药大学 一种具有防治阿尔茨海默症的新型红参的炮制工艺及其相关产品
KR20230001829A (ko) * 2021-06-29 2023-01-05 주식회사 휴사이온 20(S)-진세노사이드 Rg3를 유효성분으로 포함하는 퇴행성 뇌질환 예방 또는 치료용 약학적 조성물
CN113633650A (zh) * 2021-08-26 2021-11-12 哈尔滨工业大学（威海） 一种抑制淀粉样蛋白产生的稀有人参皂苷及其应用
CN115025106A (zh) * 2022-07-12 2022-09-09 昆明理工大学 人参皂苷Rk3在制备具有神经保护作用药物中的用途
CN115490745B (zh) * 2022-09-24 2023-12-26 昆明理工大学 人参皂苷Rh4-生物素活性分子探针及其制备方法和应用
CN116999449B (zh) * 2023-08-17 2024-05-03 吉林农业大学 一种人参皂苷组合物及其在制备多靶点脂肪细胞发育分化和代谢调节剂中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966893A (en) * 1989-01-13 1990-10-30 Pang Peter K T Method for treatment of senile dementia
KR100192678B1 (ko) * 1995-06-07 1999-06-15 손경식 약효가 증강된 가공인삼 제품
ATE275408T1 (de) * 1995-11-22 2004-09-15 Cheil Je Dang Co Verfahren zur herstellung von rg3 und rg5 ginsenosiden
AU2003201777A1 (en) * 2002-04-08 2003-10-27 Ginseng Science Inc. Novel use of the extract of processed panax genus plant and saponin compound isolated therefrom
AU2002302997A1 (en) * 2002-05-16 2004-01-19 Digital Biotech Co., Ltd. Composition for preventing or treating degenerative brain diseases comprising a hydrolysate of ginsenosides
KR20040036451A (ko) * 2002-10-26 2004-04-30 한국과학기술연구원 진세노사이드 Ｒｇ３ 또는 진세노사이드 Ｒｈ２를포함하는 글루타메이트 매개 신경독성 억제 조성물

Also Published As

Publication number Publication date
US20050245465A1 (en) 2005-11-03
WO2006124012A2 (en) 2006-11-23
CA2565002A1 (en) 2005-10-28
WO2006124012A3 (en) 2007-08-23
JP2007535578A (ja) 2007-12-06
KR20070033977A (ko) 2007-03-27
CN101133075A (zh) 2008-02-27
EP1745060A2 (en) 2007-01-24
EP1745060A4 (en) 2008-05-07

Similar Documents

Publication Publication Date Title
MXPA06012500A (es) Compuestos para el tratamiento de la enfermedad de alzheimer y para la inhibicion de la produccion del peptido beta-amiloideo.
IL258880A (en) Compounds of diarylhydantoin
WO2005013892A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
WO2006020722A3 (en) Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
WO2006037024A3 (en) Salts of decitabine
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
SG164368A1 (en) Treatment of cancer
NZ580226A (en) Dimer compounds as inhibitors of iap
ATE450251T1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
WO2006034154A3 (en) Salts of 5-azacytidine
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
TW200603746A (en) Iron sulfate based phosphate adsorbent
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
MX2007013624A (es) Inhibidores de proteina cinasa.
MX2009010378A (es) Metodos para tratar o prevenir el vomito utilizando secretagogos de hormona de crecimiento.
TW200505418A (en) Phenacyl 2-hydroxy-3-diaminoalkanes
DE502005005636D1 (en) Spirocyclische cyclohexan-derivate
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
PL1809288T3 (pl) Zastosowanie pochodnych 1,4-bis-(3-aminoalkilo)piperazyny do leczenia chorób neurodegeneracyjnych
WO2007016352A3 (en) Oral liquid losartan compositions
SG167670A1 (en) Aminocyclohexyl ether compounds and uses thereof
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
MXPA03011466A (es) Macrociclos utiles en tratamiento de enfermedades de alzheimer.
TW200730530A (en) Lyophilized compositions of a triazolopyrimidine compound
WO2007109648A8 (en) Compositions and methods for modulating store-operated calcium entry

Legal Events

Date Code Title Description
FA Abandonment or withdrawal